Bisphosphonate treatment in children with acute lymphoblastic leukemia and osteonecrosis – radiological and clinical findings in a national cohort

References

• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
   PubMed Web of Science ®Google Scholar
• Kunstreich M, Kummer S, Laws HJ, et al. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016;101(11):1295–1305.
   PubMed Web of Science ®Google Scholar
• Niinimäki R, Hansen LM, Niinimäki T, et al. Incidence of severe osteonecrosis requiring total joint arthroplasty in children and young adults treated for leukemia or lymphoma: a nationwide, register-based study in Finland and Denmark. J Adolesc Young Adult Oncol. 2013;2(4):138–144.
   PubMed Web of Science ®Google Scholar
• Mattano LA Jr., Devidas M, Nachman JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906–915.
   PubMed Web of Science ®Google Scholar
• Mostoufi-Moab S, Ward LM. Skeletal morbidity in children and adolescents during and following cancer therapy. Horm Res Paediatr. 2019;91(2):137–151.
   PubMed Web of Science ®Google Scholar
• Mogensen SS, Harila-Saari A, Mäkitie O, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(10):e27300.
   PubMed Web of Science ®Google Scholar
• Niinimäki RA, Harila-Saari AH, Jartti AE, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 2007;25(12):1498–1504.
   PubMed Web of Science ®Google Scholar
• Kuhlen M, Kunstreich M, Krull K, et al. Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge. Blood Adv. 2017;1(14):981–994.
   PubMed Web of Science ®Google Scholar
• Te Winkel ML, Pieters R, Wind EJ, et al. Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica. 2014;99(3):430–436.
   PubMed Web of Science ®Google Scholar
• Mäkitie O. Causes, mechanisms and management of paediatric osteoporosis. Nat Rev Rheumatol. 2013;9(8):465–475.
   PubMed Web of Science ®Google Scholar
• Wood CL, Ahmed SF. Bone protective agents in children. Arch Dis Child. 2018;103(5):503–508.
   PubMed Web of Science ®Google Scholar
• Padhye B, Dalla-Pozza L, Little DG, et al. Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis. Pediatr Blood Cancer. 2013;60(9):1539–1545.
   PubMed Web of Science ®Google Scholar
• Niinimäki T, Niinimäki J, Halonen J, et al. The classification of osteonecrosis in patients with cancer: validation of a new radiological classification system. Clin Radiol. 2015;70(12):1439–1444.
   PubMed Web of Science ®Google Scholar
• Niinimäki T, Harila-Saari A, Niinimäki R. The diagnosis and classification of osteonecrosis in patients with childhood leukemia. Pediatr Blood Cancer. 2015;62(2):198–203.
   PubMed Web of Science ®Google Scholar
• Te Winkel ML, Pieters R, Hop WCJ, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29(31):4143–4150.
   PubMed Web of Science ®Google Scholar
• Padhye B, Dalla-Pozza L, Little D, et al. Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). Cancer Med. 2016;5(5):960–967.
   PubMed Web of Science ®Google Scholar
• Daneshdoost SM, El Abiad JM, Ruble KJ, et al. Bisphosphonate therapy for treating osteonecrosis in pediatric leukemia patients: a systematic review. J Pediatr Hematol Oncol. 2021;43(3):e365–e370.
   PubMed Web of Science ®Google Scholar
• Mattano LA, Jr., Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18(18):3262–3272.
   PubMed Web of Science ®Google Scholar
• Niinimäki R, Suo-Palosaari M, Pokka T, et al. The radiological and clinical follow-up of osteonecrosis in cancer patients. Acta Oncol. 2019;58(4):505–511.
   PubMed Web of Science ®Google Scholar
• Tanoshima R, Carleton BC. The incidence of symptomatic osteonecrosis after allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia – controversy on dexamethasone as a risk factor. Br J Haematol. 2019;185(5):958–959.
   PubMed Web of Science ®Google Scholar
• Kuhlen M, Bader P, Sauer M, et al. Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL – results of the ALL-SCT 2003 trial. Br J Haematol. 2018;183(1):104–109.
   PubMed Web of Science ®Google Scholar